Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fractured Truth Campaign Wins Bronze Pearl Award for Content Marketing Excellence in the Healthcare/Pharmaceutical Industry
      WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) today announced that Fractured Truth—an unbranded patient campaign aimed to educate younger postmenopausal women about risks associated with osteoporosis—won the Bronze Healthcare/Pharmaceutical Industry Pearl
View HTML
Toggle Summary Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
-Elacestrant 400mg single agent Objective Response Rate (ORR) was 27.3% in heavily pre-treated patients with advanced ER+ breast cancer at the pre-determined study cutoff date of October 30, 2017- -Median PFS was 5.4 months and Clinical Benefit Rate at 24 weeks was 47.4% - -38% of study patients
View HTML
Toggle Summary Radius Health Announces Five Presentations on elacestrant (RAD1901) at the San Antonio Breast Cancer Symposium (SABCS)
SABCS to include five abstracts from the development program for elacestrant as a potential treatment of ER-positive advanced breast cancer Radius to host live webcast to discuss data presented at SABCS and provide a company update  on December 7 th at 8:00 p.m. CT / 9:00 p.m.
View HTML
Toggle Summary Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced that its Board of Directors granted Joseph Kelly, in connection with his appointment as the Company's Senior Vice President of Sales and Marketing, an option to purchase
View HTML
Toggle Summary Radius Health Announces Commercial Leadership Changes with Appointment of Joseph Kelly as Senior Vice President of Sales and Marketing, and Promotion of Amanda Mott to Senior Vice President of Market Access
WALTHAM, Mass., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the appointment of Joseph Kelly as Senior Vice President of Sales and Marketing, and the promotion of Amanda Mott to Senior Vice President of Market Access. Mr.
View HTML
Toggle Summary Radius Health Reports Third Quarter 2017 Financial and Operating Results and Provides Business Update
First full quarter of TYMLOS™ sales shows accelerating market share & stabilization of the anabolic market Plan access at approximately 200 million lives — 87% commercial and 35% Medicare Male Osteo Trial: FDA agre­ement on the design of a clinical trial in men FDA Fast Track Designation for
View HTML
Toggle Summary Radius Health Receives FDA Fast Track Designation for Elacestrant (RAD1901)
- Radius plans to initiate Phase 2 clinical study of elacestrant as a third-line therapy for women with ER+ and HER2- breast cancer early in 2018 - - Phase 2 Study is a potentially pivotal trial for accelerated approval - WALTHAM, Mass., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc.
View HTML
Toggle Summary Radius Health to Present First Health Economics Data on TYMLOS™ (abaloparatide) Injection at the Academy of Managed Care Pharmacy Nexus 2017
Five posters will cover new data on the need for osteoporosis awareness as well as cost-effectiveness data on treatment with TYMLOS WALTHAM, Mass., Oct. 13, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing and
View HTML
Toggle Summary Radius Health to Announce Third Quarter 2017 Financial Results, Host Conference Call and Live Webcast on November 2, 2017
WALTHAM, Mass., Oct. 09, 2017 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its third quarter 2017 financial results on Thursday, November 2, 2017. The Company will host a conference call and live audio webcast at 4:30 p.m.
View HTML
Toggle Summary Radius Health Initiates Phase 1 Clinical Trial of RAD140 for the Treatment of Hormone Receptor Positive Breast Cancer
Study will evaluate safety, dose and tumor response in postmenopausal women with metastatic disease
View HTML